Skip to main content
Premium Trial:

Request an Annual Quote

SARS-CoV-2 Study Documents Viral Dynamics in Young Adults With or Without Symptoms

NEW YORK – Findings from a Korean study suggest asymptomatic SARS-CoV-2 carriers may have viral loads on par with those found in symptomatic forms of infection with the coronavirus, though a slightly higher proportion of symptom-free individuals may revert to negative SARS-CoV-2 tests within a few weeks of diagnosis. 

"Because transmission by asymptomatic patients with SARS-CoV-2 may be a key factor in community spread, population-based surveillance and isolation of asymptomatic patients may be required," co-first and corresponding author Eunjung Lee, an internal medicine researcher at Soonchunhyang University, and colleagues wrote in a paper published in JAMA Internal Medicine on Thursday.

Using RT-PCR, the researchers assessed samples from 303 SARS-CoV-2-infected individuals between the ages of 22 and 36 years old who were treated at a community treatment center in the Korean city of Cheonan — a group that included 110 individuals who were symptom-free when they went into isolation.

A subset of just over 19 percent of the initially asymptomatic patients did go on to experience COVID-19 symptoms, typically within between 13 and 20 days of being isolated. But the remaining asymptomatic individuals remained free of notable symptoms over a follow-up time of between 20 and 26 days.

The team noted that viral load appeared to be comparable in the asymptomatic and symptomatic cases, based on RT-PCR cycle threshold, or Ct, values. Such results hint that symptom-free individuals may be transmitting disease, though the study did not directly test that assumption.

"In this cohort study of symptomatic and asymptomatic patients with SARS-CoV-2 infection who were isolated in a community treatment center in Cheonan, [Republic of Korea], the Ct values in asymptomatic patients were similar to those in symptomatic patients," the authors reported, calling the viral shedding in both groups "prolonged."

Notably, the study also offered a look at the proportion of patients who went on to test negative for SARS-CoV-2 over time. After two weeks, nearly 34 percent of the asymptomatic patients became SARS-CoV-2-negative based on RT-PCR testing — the proportion of negative cases grew to just over 75 percent in the symptom-free cases tested again at the day 21 post-diagnosis timepoint.

In the symptomatic COVID-19 group, the number of negative tests dipped somewhat compared to the asymptomatic groups, with 29.6 percent showing negative test conversion after 14 days and just shy of 70 percent testing negative within 21 days of diagnosis.

The authors noted that "it is possible that the asymptomatic patients in our cohort were not representative of all asymptomatic patients in the community because false negatives would not have been included in our sample," and further cautioned that "we did not determine the role that molecular viral shedding played in asymptomatic patients."

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more